Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TVGN Stock Forecast 2025-2026
$1.10
Current Price
$200.44M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TVGN Price Targets
+809.1%
To High Target of $10.00
+809.1%
To Median Target of $10.00
+809.1%
To Low Target of $10.00
TVGN Price Momentum
+8.9%
1 Week Change
+1.9%
1 Month Change
+11.1%
1 Year Change
+6.8%
Year-to-Date Change
-64.4%
From 52W High of $3.09
+329.7%
From 52W Low of $0.26
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Semper Paratus (TVGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TVGN and similar high-potential opportunities.
Latest TVGN Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, TVGN has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.10, the median forecast implies a 809.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 809.1% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 809.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TVGN Analyst Ratings
1
Buy
0
Hold
0
Sell
TVGN Price Target Range
Low
$10.00
Average
$10.00
High
$10.00
Current: $1.10
Latest TVGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TVGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Apr 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $10.00 |
Tevogen Bio Holdings Inc. (TVGN) Competitors
The following stocks are similar to Semper Paratus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tevogen Bio Holdings Inc. (TVGN) Financial Data
Tevogen Bio Holdings Inc. has a market capitalization of $200.44M with a P/E ratio of 2.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +205.7%.
Valuation Metrics
Market Cap
$200.44M
Enterprise Value
$210.85M
P/E Ratio
2.9x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.6%
Current Ratio
0.3x
Debt/Equity
-0.4x
ROE
+205.7%
ROA
-746.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Tevogen Bio Holdings Inc. (TVGN) Business Model
About Tevogen Bio Holdings Inc.
What They Do
Develops innovative cell and gene therapies.
Business Model
Tevogen Bio Holdings Inc. operates by creating advanced treatments for infectious diseases and cancers through its proprietary technology platform focused on allogeneic T-cell therapy. The company generates revenue by advancing its therapies through clinical trials and ultimately commercializing successful products in the healthcare market.
Additional Information
Tevogen Bio is committed to harnessing the human immune system for curative solutions and is recognized for its innovative approach to addressing unmet medical needs in the biotech industry, particularly in immuno-oncology and virology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
18
CEO
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.
Country
United States
IPO Year
2024
Website
tevogen.comTevogen Bio Holdings Inc. (TVGN) Latest News & Analysis
Latest News
Quick Summary
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced it received inquiries from shareholders about transferring shares to a Direct Registration System (DRS) account following a recent press release.
Why It Matters
Increased shareholder interest in the Direct Registration System may indicate growing confidence in Tevogen, potentially enhancing stock stability and attracting more institutional investment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced that CEO Dr. Ryan Saadi will participate in BioNJ's Fifteenth Annual Bio Partnering Conference on April 29, 2025.
Why It Matters
Tevogen's CEO participation in a key biotech conference could enhance visibility, attract partnerships, and indicate growth potential, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
12 days ago
Quick Summary
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has updated shareholders on key differences between holding shares in Direct Registration System (DRS) accounts versus brokerage accounts.
Why It Matters
Differences in shareholding methods can impact liquidity, voting rights, and fees, influencing investor decisions and overall stock performance for Tevogen.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced a letter of intent with CD8 Technology Services for a facility to support its cell therapy manufacturing.
Why It Matters
The partnership with CD8 enhances Tevogen's manufacturing capabilities for cell therapies, potentially boosting production efficiency and market competitiveness, positively affecting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tevogen Bio Holdings (Nasdaq: TVGN) projects $1 billion in revenue for its oncology pipeline in the launch year and estimates $10-$14 billion over five years, citing its efficient drug development model.
Why It Matters
Tevogen's reaffirmed revenue forecast signals strong growth potential in its oncology pipeline, suggesting significant future profitability and innovation, which could impact stock valuation positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tevogen Bio Announces 2025 Annual Meeting
16 days ago
Quick Summary
Tevogen Bio Holdings Inc. will hold its 2025 annual meeting on June 23, 2025, at 11 a.m. ET via webcast. Stockholders can vote on director re-elections and accounting firm ratification.
Why It Matters
Tevogen Bio's upcoming annual meeting and key votes on director re-elections and auditor ratification could influence governance and operational strategy, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TVGN Stock
What is Tevogen Bio Holdings Inc.'s (TVGN) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Tevogen Bio Holdings Inc. (TVGN) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is TVGN stock a good investment in 2025?
According to current analyst ratings, TVGN has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TVGN stock?
Wall Street analysts predict TVGN stock could reach $10.00 in the next 12 months. This represents a 809.1% increase from the current price of $1.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tevogen Bio Holdings Inc.'s business model?
Tevogen Bio Holdings Inc. operates by creating advanced treatments for infectious diseases and cancers through its proprietary technology platform focused on allogeneic T-cell therapy. The company generates revenue by advancing its therapies through clinical trials and ultimately commercializing successful products in the healthcare market.
What is the highest forecasted price for TVGN Tevogen Bio Holdings Inc.?
The highest price target for TVGN is $10.00 from Jason Kolbert at D. Boral Capital, which represents a 809.1% increase from the current price of $1.10.
What is the lowest forecasted price for TVGN Tevogen Bio Holdings Inc.?
The lowest price target for TVGN is $10.00 from Jason Kolbert at D. Boral Capital, which represents a 809.1% increase from the current price of $1.10.
What is the overall TVGN consensus from analysts for Tevogen Bio Holdings Inc.?
The overall analyst consensus for TVGN is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are TVGN stock price projections?
Stock price projections, including those for Tevogen Bio Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 6:25 PM UTC